osimertinib

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

osimertinib
Dec 20, 2024, 14:12 | Science
Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD
Yuji Uehara, Medical Oncologist, National Cancer Center, Japan, shared a post on X about a recent…
Dec 13, 2024, 15:35 | Blog
Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC
Barend Sikkema, PHD Candidate at Erasmus MC, shared a recent article on LinkedIn: "Publication Alert.…
Dec 11, 2024, 17:56 | Insight
Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “A Year…
Dec 11, 2024, 17:44 | Blog
Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC
Mediamedic shared a post on LinkedIn: "Editor’s Note: EGFR mutations are among the most common…
Dec 11, 2024, 14:33 | Blog
Sanjay Popat: Becotarug and osimertinib cohort expansion in treatment-naive EGFR mutation
Sanjay Popat, Thoracic Oncologist at The Royal Marsden NHS Foundation Trust, shared a post on…
Dec 9, 2024, 20:11 | Insight
Sanjay Popat: Stephanie Saw discusses Asian subset data from osimertinib
Sanjay Popat, Thoracic Oncologist at The Royal Marsden NHS Foundation Trust, shared on X: “Stephanie…
Dec 8, 2024, 04:47 | Insight
Exciting developments in the management of unresectable stage III EGFR NSCLC
Aakash Desai, Assistant Professor and Associate Director at UAB O'Neal Comprehensive Cancer Center, shared an…
Dec 4, 2024, 14:36 | Blog
2024 Marks The 20th Anniversary of The Discovery of EGFR in NSCLC
May 2024 Marks The 20th Anniversary of the Publication of Papers on The Role of…
Dec 2, 2024, 10:22 | Blog
Tejas Patil: The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in non-small cell lung cancer
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, posted on X about recent…
Nov 30, 2024, 19:38 | Insight
Stephen V Liu: Is there value in continuing osimertinib beyond progression?
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a recent article by Tejas…
Oct 26, 2024, 11:11 | Insight
Giuseppe Banna: Key considerations for implementing the LAURA study findings into clinical practice
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on…
Oct 20, 2024, 19:15 | Insight
Gustavo Viani: Osimertinib post-CRT as the standard of care in unresectable stage III EGFR mutated NSCLC
Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital…
Oct 7, 2024, 15:38 | Insight
Stephen V Liu: Afatinib and Bevacizumab in EGFR NSCLC
Stephen V Liu posted the following on X: “Phase II ABCD study of afatinib and…
Oct 2, 2024, 08:24 | Blog
Tanja Obradovic: FDA just approved Osimertinib for adult patients with locally advanced, unresectable non-small cell lung cancer
Tanja Obradovic shared a post on LinkedIn: ''FDA just approved Osimertinib (Tagrisso), a third-generation EGFR-directed…
Sep 29, 2024, 06:34 | Insight
Picks from Lung Cancer Cocktail With Science by Stephen V Liu
The Lung Cancer Cocktail With Science 2024 conference took place on September 27th in Milan,…
Sep 28, 2024, 07:02 | Blog
Rahul Gosain: Osimertinib now FDA approved after LAURA Phase III study
Rahul Gosain shared the following on LinkedIn: “Osimertinib now FDA approved based off LAURA: Ph III,…
Sep 26, 2024, 15:37 | Blog
Stephen V Liu: Retrospective report on treatment post osimertinib for EGFR NSCLC
Stephen V Liu shared a post on X, about recent paper published in Clinical Lung…
Sep 24, 2024, 11:04 | Blog
Stephen V Liu: The recent FDA approval of the MARIPOSA-2 regimen for EGFR NSCLC
Stephen V Liu shared a post on X: ''In this episode of the IASLC podcast…
Sep 24, 2024, 00:05 | Blog
Rahul Gosain: Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC after Osimertinib
Rahul Gosain posted on LinkedIn: "Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC…
Sep 20, 2024, 13:12 | Blog
Wafik S. El-Deiry: Dr. Matt Meyerson speaks at Dana-Farber symposium
Wafik S. El-Deiry posted the following on LinkedIn: “Dr. Matt Meyerson at Dana-Farber Cancer Institute…
Sep 14, 2024, 12:15 | Blog
Amol Akhade: Polestar vs Laura – What’s your pick?
Amol Akhade posted the following on LinkedIn: “Polestar vs Laura? Third-generation TKI post CTRT for…
Sep 11, 2024, 16:13 | Insight
RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Sep 9, 2024, 09:55 | Societies
Insights from WCLC24 by Chul Kim
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 2, 2024, 09:38 | Insight
Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of advanced EGFR-mutated NSCLC after Osimertinib
Antonio Passaro, shared a post on X: "EMA approves amivantamab in combination with chemo for…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 29, 2024, 16:56 | Insight
Stephen Liu: Overview of outcomes with 1L osimertinib
Stephen Liu shared a post on X about a recent paper by Kageaki Watanabe et…
Aug 29, 2024, 16:15 | Drugs
Antonio Passaro: European Commission approves amivantamab
Antonio Passaro shared on LinkedIn: "I'm proud to announce that, yesterday August 27, the European…
Aug 27, 2024, 22:13 | Insight
Stephen Liu: Final anaysis of WJOG9717L
Stephen Liu shared a post on X: “Final anaysis of WJOG9717L (phase II osimertinib +/-…
Aug 27, 2024, 21:52 | Blog
David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA
David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post…
Aug 26, 2024, 21:24 | Blog
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC
Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 23, 2024, 14:21 | Drugs
Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?
Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…
Aug 14, 2024, 13:49 | Insight
Amol Akhade: New and exciting data coming up at WLCC 24
Amol Akhade shared on X about recent papers: "What's new and exciting data coming up…
Aug 8, 2024, 13:30 | Blog
MARIPOSA for EGFR-mutant lung cancer - EGFR Positive UK
EGFR Positive UK shared a post on X: ''Interesting discussion re future of osimertinib following…
Aug 6, 2024, 06:07 | Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Jul 27, 2024, 10:23 | Blog
C S Pramesh: Welcome move to exempt some important cancer medicines from customs duty
C S Pramesh, Director of the Tata Memorial Hospital and the Professor and Head of…
Jul 24, 2024, 13:40 | Blog
Collin Blakely: Neoadjuvant Osimertinib for the Treatment of Non–Small Cell Lung Cancer
Collin Blakely, Associate Professor of Thoracic Medical Oncology and Clinical Scientist at UCSF, shared a…
Jul 22, 2024, 02:59 | Blog
CtDNA Analysis on Osimertinib in FLAURA and AURA3 trials
Jarushka Naidoo shared a post on X about an article by Jhanelle Gray et al. titled…
Jul 21, 2024, 13:36 | Blog
Rami Manochakian: Neoadjuvant osimertinib in stage I-IIIA EGFRm NSCLC did not meet primary endpoint
Rami Manochakian shared a post on X: ''Hot off the press. Neoadjuvant Osimertinib for the…
Jul 19, 2024, 22:55 | Blog
What after Osimertinib failure?
Abhishek Pathak, Professor at the Indian Army, shared a post on X: "What after Osimertinib…
Jul 12, 2024, 23:07 | Insight
Osimertinib could change the standard of care for EGFR-mutant NSCLC
Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X: "Osimertinib could change…
Jul 2, 2024, 04:16 | Insight
Olivier Calvayrac: TT-derived drug-tolerant (DT) lung cancer cells are vulnerable to FTIs
Olivier Calvayrac, Research Scientist at the Toulouse Cancer Research Center, shared a post on X…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 26, 2024, 12:05 | Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 21, 2024, 09:39 | Insight
Stephanie Saw: Real-world evidence of adding pemetrexed-platinum chemotherapy upon osimertinib progression
Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, shared on X/Twitter: "Just out in…
Jun 10, 2024, 11:09 | Insight
Phase II BLOSSOM Trial Osimertinib in LMD from EGFR+ NSCLC by Sehhoon Park et al.
Jarushka Naidoo shared a post on X: "Phase II BLOSSOM Trial Osimertinib in LMD (leptomeningeal…
Jun 10, 2024, 00:53 | Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
Jun 4, 2024, 04:18 | Blog
Narjust Florez: So lucky to call Dr. Lecia Sequist my mentor
Narjust Florez shared a post on X: "So lucky to call this amazing physician my…
May 29, 2024, 12:03 | Insight
Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
Eric Singhi shared on X:  "MARIPOSA: Amivantamab + lazertinib v osimertinib in 1L EGFR+ mNSCLC:…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 26, 2024, 06:31 | Insight
Vivek Subbiah: Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma
Vivek Subbiah shared a post on X/Twitter: "Impressive response to dabrafenib, trametinib, and osimertinib in a…
May 25, 2024, 14:28 | Blog
Studies conducted by Dana-Farber at this year’s AACR Annual Meeting
Dana-Farber Cancer Institute shared on LinkedIn: "Numerous studies conducted by Dana-Farber researchers show promising results for…
May 23, 2024, 07:56 | Blog
Chinmay Jani: Let's explore EGFR Exon 20 Insertion NSCLC with a twist of Miami flair!
Chinmay Jani, Clinical Fellow, Hematology & Oncology at University of Miami, made the following post…
Apr 23, 2024, 18:57 | Insight
New Paper Alert! Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of the Literature
Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of…
Apr 13, 2024, 09:17 | Societies
30 Posts Not To Miss From AACR24!
The AACR Annual Meeting 2024 was held from April 5th to 10th in San Diego,…
Apr 12, 2024, 11:46 | Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Apr 4, 2024, 13:34 | Drugs
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "NSCLC and anti-EGFR treatments…
Feb 28, 2024, 18:42 | Drugs
Amalya Sargsyan: Excitement around osimertinib in the NSCLC community
Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn: "Huge…
Feb 23, 2024, 14:31 | Blog
Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least
Rasika Bombatkar, Citizen Scientist at LUNGevity Foundation, cancer patient and advocate, shared on X: "AstraZeneca,…
Feb 17, 2024, 15:57 | Insight
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: "Hot off…
Feb 7, 2024, 12:46 | Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
Feb 5, 2024, 11:27 | Insight
Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Jan 16, 2024, 05:48 | Drugs
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Nov 28, 2023, 18:00 | Drugs
Stephen V Liu: Report on real world efficacy and safety of amivantamab including off label use
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at the Lombardi Comprehensive Cancer…
Nov 12, 2023, 17:56 | Drugs
David Planchard: Thank you to the patients who actively participated in this research
David Planchard, Professor at the University Paris Saclay, posted on X/Twitter. "Proud to lead this…
Oct 29, 2023, 03:16 | Drugs
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…
Oct 17, 2023, 16:44 | Insight
Stephen V Liu reflected on the OCEAN study published in the Journal of Thoracic Oncology
Quoting Stephen V Liu, Associate Professor of Medicine and the Director of Thoracic Oncology at Georgetown…
Jul 23, 2023, 17:05 | Blog
ASCO expert panel chaired by Navneet Singh and Megan Daly has published an update on management of stage III NSCLC based on the ADAURA and KEYNOTE-671 trials - Navneet Singh
All: 70 Posts: 1 - 100
Special Coverage